SULANDA\u00ae is the commercial brand name of Surufatinib Capsules, an oral small-molecule multi-target tyrosine kinase inhibitor independently developed by HUTCHMED. It inhibits VEGFR, FGFR and CSF-1R simultaneously, exerting dual anti-angiogenic and immune-modulating anti-tumor effects.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy SULANDA (Surufatinib Capsules)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" SULANDA\u00ae is the commercial brand name of Surufatinib Capsules, an oral small-molecule multi-target tyrosine kinase inhibitor independently developed by HUTCHMED. It inhibits VEGFR, FGFR and CSF-1R simultaneously, exerting dual anti-angiogenic and immune-modulating anti-tumor effects. Main IndicationsMonotherapy for unresectable locally advanced or metastatic progressive, well-differentiated (G1\/G2) pancreatic and extrapancreatic neuroendocrine tumors. Common Side EffectsCommon mild adverse […]<\/p>\n","protected":false},"author":4,"featured_media":4253,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-4252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Monotherapy for unresectable locally advanced or metastatic progressive, well-differentiated (G1\/G2) pancreatic and extrapancreatic neuroendocrine tumors.<\/p>\n\n\n\n
Common mild adverse reactions: Hypertension, proteinuria, diarrhea, fatigue, abdominal pain, elevated transaminases and hypothyroidism;
Laboratory abnormalities: Elevated urinary protein, decreased hemoglobin, elevated liver enzymes;
Severe but uncommon risks: Severe hypertension crisis, severe proteinuria leading to nephrotic syndrome, hemorrhage events and gastrointestinal perforation.<\/p>\n\n\n\n
SULANDA\u00ae (Surufatinib Capsules, 50 mg) was first approved for marketing in China in December 2020 for extrapancreatic neuroendocrine tumors, and expanded approval for pancreatic neuroendocrine tumors was obtained in June 2021. It is a prescription targeted anti-tumor drug included in China\u2019s Category B medical insurance list.<\/p>\n\n\n\n